Skip to main content
Live · TradingView
Back to the NewsWire

App Dealroom

Published September 10, 2026 · Updated September 11, 2026

Optimi Health to run 200-patient Phase 2 trial of natural psilocybin for major depressive disorder

Read the full story at App Dealroom

It marks a strategic broadening from commercial manufacturing — Optimi already supplies prescribed psilocybin and MDMA products in Australia and.

Surfaced by this Google Alert

  • MDMA